http://rdf.ncbi.nlm.nih.gov/pubchem/reference/6515321

Outgoing Links

Predicate Object
contentType Comparative Study|English Abstract|Journal Article|Multicenter Study|Randomized Controlled Trial
endingPage 9
issn 0385-0684
issueIdentifier 10
pageRange 1423-9
publicationName Gan to kagaku ryoho. Cancer & chemotherapy
startingPage 1423
bibliographicCitation Inaji H, Sakai K, Oka T, Ozawa K, Saito Y, Senoo T, Taguchi T, Terasawa T, Nakao K, Mori T, Koyama H, Oshima A. [A randomized controlled study comparing uracil-tegafur (UFT)+tamoxifen (UFT+TAM therapy) with cyclophosphamide+adriamycin+5-fluorouracil (CAF therapy) for women with stage I , II, or IIIa breast cancer with four or more involved nodes in the adjuvant setting]. Gan To Kagaku Ryoho. 2006 Oct;33(10):1423–9. PMID: 17033231.
creator http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6abf67a9ac3f339e3efb1ec10dd4c502
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4b7f58481a378cc0498d11c0f3d4d3be
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_506984e4d20313fdb895da3f0cc96c88
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e391fbc0003bf95bbc242544f2d2b9dc
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b8675662f59bafd6958c42a6e4cb1128
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_11a9a7ee3f12d3bc0428965db15437c1
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_94906b4569ea6e8d99ac2b2b0cf057d2
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f8bc4042c806a9df7f7bd2ee7afca776
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7e5b11a44f632782dfd038d0aa9cfa24
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1d3d090b3a1dfd4e9f8006c2c26a839b
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_60dc711274cf8db42668ee2ef3ac75b4
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d982284f347d5924d57ec84918c3bde2
date 200610
identifier https://pubmed.ncbi.nlm.nih.gov/17033231
isPartOf https://portal.issn.org/resource/ISSN/0385-0684
http://rdf.ncbi.nlm.nih.gov/pubchem/journal/718
language Japanese
source https://pubmed.ncbi.nlm.nih.gov/
title [A randomized controlled study comparing uracil-tegafur (UFT)+tamoxifen (UFT+TAM therapy) with cyclophosphamide+adriamycin+5-fluorouracil (CAF therapy) for women with stage I , II, or IIIa breast cancer with four or more involved nodes in the adjuvant setting]
discusses http://id.nlm.nih.gov/mesh/M0008631
http://id.nlm.nih.gov/mesh/M0028300
http://id.nlm.nih.gov/mesh/M0006784
http://id.nlm.nih.gov/mesh/M0022302
http://id.nlm.nih.gov/mesh/M0008871
http://id.nlm.nih.gov/mesh/M0005485
http://id.nlm.nih.gov/mesh/M0021024
hasPrimarySubjectTerm http://id.nlm.nih.gov/mesh/D008198Q000473
http://id.nlm.nih.gov/mesh/D000971Q000627
http://id.nlm.nih.gov/mesh/D001943Q000188
http://id.nlm.nih.gov/mesh/D001943Q000473
hasSubjectTerm http://id.nlm.nih.gov/mesh/D014498Q000008
http://id.nlm.nih.gov/mesh/D008875
http://id.nlm.nih.gov/mesh/D001943Q000601
http://id.nlm.nih.gov/mesh/D015996
http://id.nlm.nih.gov/mesh/D004334
http://id.nlm.nih.gov/mesh/D007970Q000139
http://id.nlm.nih.gov/mesh/D009367
http://id.nlm.nih.gov/mesh/D014840Q000209
http://id.nlm.nih.gov/mesh/D000971Q000009
http://id.nlm.nih.gov/mesh/D000971Q000008
http://id.nlm.nih.gov/mesh/D018931Q000008
http://id.nlm.nih.gov/mesh/D004317Q000008
http://id.nlm.nih.gov/mesh/D001943Q000401
http://id.nlm.nih.gov/mesh/D005260
http://id.nlm.nih.gov/mesh/D005641Q000008
http://id.nlm.nih.gov/mesh/D003520Q000008
http://id.nlm.nih.gov/mesh/D000855Q000139
http://id.nlm.nih.gov/mesh/D013629Q000008
http://id.nlm.nih.gov/mesh/D017024
http://id.nlm.nih.gov/mesh/D008408
http://id.nlm.nih.gov/mesh/D005472Q000008
http://id.nlm.nih.gov/mesh/D003131
http://id.nlm.nih.gov/mesh/D006801
http://id.nlm.nih.gov/mesh/D008207
discussesAsDerivedByTextMining http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7706
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2907
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID31703
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9614
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7102
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8321
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID6910
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID104747
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8382
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8593
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID6847
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2733526
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3385

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128212147
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128713593
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID135789409
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127952853
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129575636

Total number of triples: 80.